NO20064974L - terapeutiske midler - Google Patents

terapeutiske midler

Info

Publication number
NO20064974L
NO20064974L NO20064974A NO20064974A NO20064974L NO 20064974 L NO20064974 L NO 20064974L NO 20064974 A NO20064974 A NO 20064974A NO 20064974 A NO20064974 A NO 20064974A NO 20064974 L NO20064974 L NO 20064974L
Authority
NO
Norway
Prior art keywords
therapeutic agents
compounds
psychiatric
obesity
processes
Prior art date
Application number
NO20064974A
Other languages
English (en)
Inventor
Eva-Lotte Lindstedt Alstermark
Anna Maria Persdotter Boije
Leifeng Cheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064974(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0407671A external-priority patent/GB0407671D0/en
Priority claimed from GB0420781A external-priority patent/GB0420781D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20064974L publication Critical patent/NO20064974L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Foreliggende oppfinnelse angår forbindelser med formel I og prosesser for fremstilling av slike forbindelser, anvendelse av dem ved behandling av fedme, psykiatriske og nevrologiske lidelser, til metoder for deres terapeutiske anvendelse og til farmasøytiske preparater inneholdende dem.
NO20064974A 2004-04-03 2006-10-31 terapeutiske midler NO20064974L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0407671A GB0407671D0 (en) 2004-04-03 2004-04-03 Therapeutic agents
GB0420781A GB0420781D0 (en) 2004-09-18 2004-09-18 Therapeutic agents
PCT/GB2005/001153 WO2005095354A1 (en) 2004-04-03 2005-03-30 Therapeutic agents

Publications (1)

Publication Number Publication Date
NO20064974L true NO20064974L (no) 2006-10-31

Family

ID=34963354

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064974A NO20064974L (no) 2004-04-03 2006-10-31 terapeutiske midler

Country Status (14)

Country Link
US (1) US7799804B2 (no)
EP (1) EP1735287A1 (no)
JP (1) JP4177435B2 (no)
KR (1) KR20060133084A (no)
AR (1) AR049487A1 (no)
AU (1) AU2005229459B9 (no)
BR (1) BRPI0509515A (no)
CA (1) CA2560417C (no)
IL (1) IL178427A0 (no)
NO (1) NO20064974L (no)
RU (1) RU2377238C2 (no)
TW (1) TW200539872A (no)
UY (1) UY28839A1 (no)
WO (1) WO2005095354A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6526575B1 (en) 1997-01-07 2003-02-25 United Video Properties, Inc. System and method for distributing and broadcasting multimedia
JP2008525401A (ja) * 2004-12-23 2008-07-17 アストラゼネカ アクチボラグ 治療薬
GB0518817D0 (en) * 2005-09-15 2005-10-26 Astrazeneca Ab Therapeutic agents
GB0518819D0 (en) * 2005-09-15 2005-10-26 Astrazeneca Ab Therapeutic agents
AR056560A1 (es) 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
BRPI0709972A2 (pt) 2006-04-14 2011-08-02 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
JP2009533445A (ja) 2006-04-14 2009-09-17 メルク エンド カムパニー インコーポレーテッド コレシストキニン−１受容体モジュレータとしての置換イミダゾール４−カルボキサミド
WO2007120718A2 (en) 2006-04-14 2007-10-25 Merck & Co., Inc. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
US20100113492A1 (en) 2007-01-26 2010-05-06 Merck & Co., Inc. Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
ES2586433T3 (es) 2007-04-11 2016-10-14 Omeros Corporation Composiciones y métodos para la profilaxis y el tratamiento de adicciones
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2014199164A1 (en) * 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE140966C (no)
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
CN1205188C (zh) * 2000-03-23 2005-06-08 索尔瓦药物有限公司 具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
AR036608A1 (es) 2001-09-24 2004-09-22 Bayer Corp Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad
WO2003063781A2 (en) 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
ES2373875T3 (es) 2002-03-05 2012-02-09 Transtech Pharma, Inc. Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage.
WO2003075660A1 (en) 2002-03-06 2003-09-18 Merck & Co., Inc. Method of treatment or prevention of obesity
US6799511B2 (en) * 2002-12-03 2004-10-05 Day International, Inc. Gapless compressible cylinder assembly
WO2004060367A1 (en) 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
PL378206A1 (pl) 2003-01-02 2006-03-20 F. Hoffmann-La Roche Ag Nowi odwrotni agoniści receptora CB1
MXPA05011855A (es) 2003-05-08 2006-02-17 Astellas Pharma Inc 1,2-diarilimidazoles utiles como inhibidores de ciclooxigenasa.

Also Published As

Publication number Publication date
AU2005229459A1 (en) 2005-10-13
BRPI0509515A (pt) 2007-09-11
AR049487A1 (es) 2006-08-09
CA2560417C (en) 2011-04-19
CA2560417A1 (en) 2005-10-13
UY28839A1 (es) 2005-11-30
AU2005229459B2 (en) 2008-09-25
RU2006135482A (ru) 2008-05-10
AU2005229459B9 (en) 2009-01-22
IL178427A0 (en) 2007-02-11
RU2377238C2 (ru) 2009-12-27
JP2007531723A (ja) 2007-11-08
US20070208059A1 (en) 2007-09-06
TW200539872A (en) 2005-12-16
EP1735287A1 (en) 2006-12-27
JP4177435B2 (ja) 2008-11-05
US7799804B2 (en) 2010-09-21
KR20060133084A (ko) 2006-12-22
WO2005095354A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
NO20063787L (no) Terapeutiske preparater
NO20064974L (no) terapeutiske midler
TW200504034A (en) Therapeutic agents
TW200635903A (en) Therapeutic agents
TW200633986A (en) Therapeutic agents
NO20081523L (no) Fremstilling og anvendelse av tetrahydropyrrolo(3,2-C)Pyridin-4-on-derivater for behandling av fedme, psykiatriske og neurologiske forstyrrelser
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
TW200611695A (en) Pyrrolopyridine derivatives
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
NO330888B1 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling av slike, terapeutisk preparatinneholdende slike samt anvendelse av slike for fremstilling av preparat for behandling av sykdom
MXPA05013075A (es) Inhibidores de p-38 basados en heterociclo de 5 miembros.
NO20053792L (no) Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander
NO20055919L (no) 3-Subtituerte,5,6-Diaryl-Pyrazin-2-Karboksamid og 2-Sulfonamidderivater som CB1-Modulatorar
NO20060446L (no) Trisykliske delta-opioidmodulatorer
NO20073615L (no) 3, 5-disubstituert og 3, 5, 7-trisubstituert-3H-oksazolo og 3H-tiazolo [4,5-d]pyrimidin-2-on forbindelser og prodrug derav
GEP20084420B (en) Use of imidazole compounds for the treatment of neurodegenerative disorders
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
NO20080372L (no) Pyrazolderivater som teraputiske midler
NO20082496L (no) Pyrazinderivater
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
NO20080969L (no) 1,2-diarylimidazoler for anvendelse som CBI-modulatorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application